ATE225181T1 - Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen - Google Patents

Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen

Info

Publication number
ATE225181T1
ATE225181T1 AT98925774T AT98925774T ATE225181T1 AT E225181 T1 ATE225181 T1 AT E225181T1 AT 98925774 T AT98925774 T AT 98925774T AT 98925774 T AT98925774 T AT 98925774T AT E225181 T1 ATE225181 T1 AT E225181T1
Authority
AT
Austria
Prior art keywords
molecular weight
low molecular
treatment
brain edema
weight heparins
Prior art date
Application number
AT98925774T
Other languages
English (en)
Inventor
Veronique Mary
Jeremy Pratt
Jean-Marie Stutzmann
Andre Uzan
Florence Wahl
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE225181T1 publication Critical patent/ATE225181T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT98925774T 1997-05-28 1998-05-25 Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen ATE225181T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9706551A FR2763849B1 (fr) 1997-05-28 1997-05-28 Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
PCT/FR1998/001035 WO1998053834A1 (fr) 1997-05-28 1998-05-25 Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux

Publications (1)

Publication Number Publication Date
ATE225181T1 true ATE225181T1 (de) 2002-10-15

Family

ID=9507336

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98925774T ATE225181T1 (de) 1997-05-28 1998-05-25 Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen

Country Status (24)

Country Link
US (1) US6579858B1 (de)
EP (1) EP0984787B1 (de)
JP (1) JP2002502387A (de)
KR (1) KR100562425B1 (de)
CN (1) CN1223351C (de)
AT (1) ATE225181T1 (de)
AU (1) AU742995B2 (de)
BR (1) BR9809180A (de)
CA (1) CA2290682A1 (de)
DE (1) DE69808455T2 (de)
DK (1) DK0984787T3 (de)
ES (1) ES2182321T3 (de)
FR (1) FR2763849B1 (de)
IL (2) IL132670A0 (de)
MA (1) MA24554A1 (de)
NO (1) NO317003B1 (de)
NZ (1) NZ501366A (de)
PE (1) PE73099A1 (de)
PT (1) PT984787E (de)
RU (1) RU2195287C2 (de)
TN (1) TNSN98072A1 (de)
TW (1) TW546141B (de)
WO (1) WO1998053834A1 (de)
ZA (1) ZA984433B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787329B1 (fr) * 1998-12-17 2001-02-09 Aventis Pharma Sa Nouvelle application therapeutique des heparines de bas poids moleculaire
JP2005505537A (ja) * 2001-08-28 2005-02-24 レオ・ファーマ・アクティーゼルスカブ 低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物
RU2238737C1 (ru) * 2003-04-17 2004-10-27 Закрытое Акционерное Общество Научно-Производственный Центр "Борщаговский Химико-Фармацевтический Завод" Препарат "веногепанол" для лечения и профилактики патологических поражений сосудов и тканей
ITMI20031023A1 (it) * 2003-05-21 2004-11-22 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013092C1 (ru) * 1989-02-27 1994-05-30 Дагестанский государственный медицинский институт Способ лечения отека мозга при туберкулезном менингоэнцефалите

Also Published As

Publication number Publication date
PT984787E (pt) 2003-01-31
TW546141B (en) 2003-08-11
NZ501366A (en) 2000-11-24
CA2290682A1 (fr) 1998-12-03
JP2002502387A (ja) 2002-01-22
IL132670A0 (en) 2001-03-19
TNSN98072A1 (fr) 2005-03-15
MA24554A1 (fr) 1998-12-31
DE69808455D1 (de) 2002-11-07
US6579858B1 (en) 2003-06-17
DE69808455T2 (de) 2003-07-03
NO995539D0 (no) 1999-11-12
ES2182321T3 (es) 2003-03-01
KR100562425B1 (ko) 2006-03-17
FR2763849B1 (fr) 2000-09-15
AU742995B2 (en) 2002-01-17
IL132670A (en) 2010-05-31
PE73099A1 (es) 1999-10-21
EP0984787B1 (de) 2002-10-02
RU2195287C2 (ru) 2002-12-27
EP0984787A1 (de) 2000-03-15
CN1223351C (zh) 2005-10-19
FR2763849A1 (fr) 1998-12-04
WO1998053834A1 (fr) 1998-12-03
ZA984433B (en) 1998-12-28
DK0984787T3 (da) 2003-02-03
KR20010013073A (ko) 2001-02-26
CN1257429A (zh) 2000-06-21
BR9809180A (pt) 2000-08-01
NO995539L (no) 1999-11-12
NO317003B1 (no) 2004-07-19
AU7776098A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
DE69834724D1 (de) Behandlung von Darm- oder Blasenentzündungen
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE69619051D1 (de) Behandlung von Füllstoffen mit Oxasilacycloalkanen
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69313261D1 (de) Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS
DE69924979D1 (de) Behandlung von chronischen schmerzen
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen
EA199800818A1 (ru) Способ лечения бессонницы
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE96129T1 (de) Behandlung von abwasser.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0984787

Country of ref document: EP

REN Ceased due to non-payment of the annual fee